Argenx Se (ARGX) Non-Current Deferred Tax Liability (2020 - 2024)

Argenx Se's (ARGX) quarterly Non-Current Deferred Tax Liability came in at $5.0 million in Q2 2024, down 43.85% YoY from $8.9 million in Q3 2023, and down 3.12% on a QoQ basis from $5.2 million in Q4 2023.

Argenx Se (ARGX) Non-Current Deferred Tax Liability (2020 - 2024) Analysis & Trends

Argenx Se (ARGX) has 5 years of Non-Current Deferred Tax Liability data on file, last reported at $5.0 million in Q2 2024.

  • Quarterly Non-Current Deferred Tax Liability fell 43.85% year-over-year to $5.0 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $5.0 million (down 43.85% YoY) and the FY2023 annual result came in at $5.2 million, down 38.67% from the prior year.
  • Non-Current Deferred Tax Liability eased to $5.0 million in Q2 2024, from $5.2 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $12.4 million in Q2 2021 to a low of $959371.8 in Q2 2020.
  • A 5-year average of $6.3 million and a median of $6.4 million in 2021 frame the typical range for Non-Current Deferred Tax Liability.
  • Annual changes were most pronounced in 2021 — Non-Current Deferred Tax Liability soared 1191.26% — and 2024, when it sank 43.85%.
  • Tracing ARGX's Non-Current Deferred Tax Liability over 5 years: stood at $1.4 million in 2020, then jumped by 345.52% to $6.4 million in 2021, then jumped by 30.57% to $8.4 million in 2022, then slumped by 38.67% to $5.2 million in 2023, then slipped by 3.12% to $5.0 million in 2024.
  • The last three Non-Current Deferred Tax Liability figures came in at $5.0 million (Q2 2024), $5.2 million (Q4 2023), and $8.9 million (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Roivant Sciences 26.16 Bn 26.85 Bn 1.16 Mn

Historic Data

Download Data
DateValue
Jun 30, 2024 4.99 Mn
Jun 30, 2024 4.99 Mn
Dec 31, 2023 5.16 Mn
Dec 31, 2023 5.16 Mn
Jun 30, 2023 8.89 Mn
Jun 30, 2023 8.89 Mn
Dec 31, 2022 8.41 Mn
Dec 31, 2022 8.41 Mn
Jun 30, 2022 7.66 Mn
Jun 30, 2022 7.66 Mn
Dec 31, 2021 6.44 Mn
Dec 31, 2021 6.44 Mn
Jun 30, 2021 12.39 Mn
Jun 30, 2021 12.39 Mn
Dec 31, 2020 1.45 Mn
Dec 31, 2020 1.45 Mn
Jun 30, 2020 959,371.77
Jun 30, 2020 959,371.77